<DOC>
	<DOCNO>NCT00918957</DOCNO>
	<brief_summary>This study design show well tobramycin inhalation powder work safe produce modified manufacturing process</brief_summary>
	<brief_title>A Study Tobramycin Inhalation Powder From Modified Manufacturing Process Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Written inform consent give adult parents/legal guardian combination patient 's assent , capable assenting , assessment perform Confirmed diagnosis Cystic Fibrosis ( CF ) presence one clinical feature CF addition : quantitative pilocarpine iontophoresis sweat chloride test &gt; 60 mEq/L ; identification wellcharacterized diseasecausing mutation CFTR gene ; abnormal nasal transepithelial potential difference characteristic CF . Forced Expiratory Volume one second ( FEV1 ) screen must ≥25 % ≤80 % normal predict value age , sex , height base Knudson criterion P. aeruginosa must present sputum/deepthroat cough swab culture ( bronchoalveolar lavage [ BAL ] ) within 6 month prior screen sputum/deepthroat cough swab culture screen visit Able expectorate sputum sample provide deep throat cough swab screen Able comply protocol requirement Use effective mean contraception female childbearing potential Clinically stable opinion investigator treat accord protocol FEV1 baseline ( Visit 2 ) &lt; 25 % &gt; 80 % normal predict value age , sex , height base Knudson criterion , and/or FEV1 baseline ( Visit 2 ) deviate ≥10 % FEV1 measure screening ( Visit 1 ) Any use inhale antipseudomonal antibiotic within 4 month prior screen Any use systemic antipseudomonal antibiotic within 28 day prior study drug administration Serum creatinine 2 mg/dL , blood urea nitrogen ( BUN ) 40 mg/dL , abnormal urinalysis define 2+ great proteinuria Known local systemic hypersensitivity aminoglycosides inhale antibiotic Signs symptom acute pulmonary disease , e.g . pneumonia , pneumothorax Administration investigational drug within 30 day prior enrollment Any previous exposure tobramycin dry powder inhalation ( TIP ) Administration loop diuretic within 7 day prior study drug administration Initiation treatment chronic macrolide therapy within 28 day prior study drug administration Initiation treatment dornase alfa within 28 day prior study drug administration Initiation treatment inhale steroid ( increase dose ) within 28 day prior study drug administration Initiation treatment inhale hypertonic saline ( HS ) within 28 day prior study drug administration Personal history abnormal hear family history abnormal hearing typical hearing loss associate age process Known abnormal result audiology test ( define either unilateral puretone audiometry test show threshold elevation &gt; 20 dB frequency across frequency range 0.25 kHz 8 kHz absence emission evoke otoacoustic emission test ) History sputum culture throat swab ( BAL ) culture yield Burkholderia cepacia ( B. cepacia ) within 2 year prior screen and/or sputum culture yield B. cepacia screen Hemoptysis 60 mL time within 30 day prior study drug administration History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless evidence local recurrence metastasis Patients clinically significant laboratory abnormality ( associate study indication ) screening Patients caregiver history noncompliance medical regimen patient caregiver consider potentially unreliable Pregnant nursing ( lactate ) woman Women childbearing potential unless use two reliable birth control methods Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Tobramycin Inhalation Powder</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Lung disease</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Treatment infection P. aeruginosa cystic fibrosis subject</keyword>
</DOC>